Danazol therapy in hormone-sensitive mammary carcinoma.
The effect of Danazol, a synthetic gonadotropin inhibitor, on two groups of Sprague-Dawley rats with dimethylbenze (a) anthracine (DMBA) induced mammary carcinoma was studied. Twenty-four (83%) of 29 control animals developed mammary tumors. Forty-four rats in one treatment group received Danazol after tumor reached 0.5 cm in diameter. Twenty-nine (66%) demonstrated tumor regression (p less than 0.005) and in 16 (36%) tumor disappeared (p less than 0.005). In a second treatment group (given Danazol daily after administration of DMBA), only seven of 50 rats (14%) developed palpable mammary carcinoma (p less than 0.0005). Danazol therapy resulted in regression of established mammary carcinoma in rats, and produced a striking inhibition of carcinogenesis in those animals treated from the time DMBA was administered. Danazol is clinically safe; studies using it in the treatment of breast cancer in women who are candidates for hormonal ablative therapy seem warranted.
D015127:9,10-Dimethyl-1,2-benzanthracene; D000818:Animals; D003613:Danazol / Q000008:administration & dosage / Q000627:therapeutic use*; D004702:Endocrine Glands / Q000503:physiopathology; D005260:Female; D006728:Hormones / Q000502:physiology; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D011245:Pregnadienes / Q000627:therapeutic use*; D051381:Rats; D012075:Remission, Spontaneous
D006728:Hormones; D011245:Pregnadienes; D015127:9,10-Dimethyl-1,2-benzanthracene; D003613:Danazol